Innovative AAV Manufacturing Platform

FUEL™

As gene therapy developers push the boundaries of innovation, manufacturing must keep pace. Forge’s FUEL™ platform delivers a more efficient manufacturing foundation — with advanced technologies, proven processes, and product-specific optimizations to propel your program forward.

advanced technology

pEMBR™ 2.0 Ad Helper

As one of the smallest Ad helpers commercially available at 8.9 kb, pEMBR™ 2.0 increases manufacturing efficiency, offers an improved safety profile by reducing unnecessary adenoviral components for AAV production, and is Forge-specific intellectual property.

advanced technology

Modified Rep/Caps

Designed for safety and higher AAV yields, Forge’s patent pending modified rep/cap incorporates the client-specific capsid sequence into its proprietary backbone plasmid.

HEK293 Ignition Cells™

advanced technology

Ignition Cells™

Our suspension HEK293 Ignition Cells™ are optimized for robust transient transfection and can achieve over 90% full capsids post-enrichment, often with undetectable particles. Ignition Cells™ are supported by fully qualified Master Cell Bank and Working Cell Bank.

Novel Capsid? Yeah, Our Platform Can Work With That.

The FUEL™ platform is designed to support all serotypes, including novel capsids.

Higher Yield, Better Recovery, Same Unmatched Quality

Explore how FUEL™ boosts productivity, scales seamlessly, improves recovery, and maintains consistent quality.

Insights

Access Deeper Insights on FUEL™ in This Technical Article
Ready to FUEL your program?

Ready to Fuel Your Program?

Let’s talk about how we can help accelerate your therapy to patients.

Hot off the Forge